A new once-daily cholesterol pill called Lipfendra (enlicitide) is the first oral PCSK9 inhibitor approved by the FDA. Learn how it works, who may benefit, and what the research shows.
For people struggling to lower their LDL cholesterol, a new treatment option may make cholesterol management more convenient.
In July 2026, the U.S. Food and Drug Administration approved Lipfendra (enlicitide), a once-daily oral medication that lowers LDL cholesterol. It is the first PCSK9 inhibitor available as a pill rather than an injection.
The approval is significant because PCSK9 inhibitors have traditionally been available as injectable medications.
What Is LDL Cholesterol?
LDL stands for low-density lipoprotein.
It is often called “bad” cholesterol because excessive LDL cholesterol can contribute to plaque buildup inside arteries. Over time, this can increase the risk of cardiovascular problems such as heart attack and stroke.
High LDL cholesterol often causes no noticeable symptoms, which is why blood testing is important.
What Is Lipfendra?
Lipfendra is the brand name for enlicitide.
It belongs to a class of medicines called PCSK9 inhibitors. The medication blocks PCSK9, a protein involved in the liver’s regulation of LDL receptors.
By interfering with this process, the drug helps the liver remove more LDL cholesterol from the bloodstream.
It is taken as a once-daily oral tablet and is intended to be used alongside diet and exercise.
How Much Can It Lower LDL?
The results from the clinical trials were substantial.
The FDA reported that in one trial, people receiving Lipfendra experienced an average 56% reduction in LDL cholesterol at Week 24 compared with placebo.
In another trial involving people with heterozygous familial hypercholesterolemia, the average reduction was 59% compared with placebo.
The trials included more than 3,200 adults with high cholesterol, including people with and without inherited high cholesterol.
Why Is an Oral PCSK9 Inhibitor Important?
Until now, PCSK9 inhibitors have primarily been available as injections.
For some people, injections can be inconvenient or uncomfortable. A daily tablet may provide another option for people who need additional LDL lowering.
Harvard Health notes that the new medication may be particularly useful for people who cannot tolerate statins or whose LDL remains too high despite existing cholesterol treatment.
Does This Mean Statins Are No Longer Necessary?
No.
Statins remain an important foundation of cholesterol treatment for many people.
The 2026 ACC/AHA cholesterol guidelines continue to emphasize lifestyle changes and statin therapy when appropriate. Other medications may be added when LDL cholesterol remains above the desired level or when a person cannot tolerate standard treatment.
Depending on a person’s individual cardiovascular risk, doctors may consider medications such as ezetimibe, bempedoic acid, or PCSK9-targeting treatments.
What Side Effects Were Reported?
In the clinical trials, the overall frequency of adverse reactions was similar between Lipfendra and placebo in one major study.
In the trial involving people with heterozygous familial hypercholesterolemia, diarrhea and dizziness occurred more frequently with Lipfendra than with placebo.
That does not mean everyone taking the medication will experience these effects.
As with any prescription medication, treatment decisions should be made with a healthcare professional who knows the patient’s medical history and other medications.
Is It a Replacement for a Healthy Diet?
No.
The FDA approval specifically describes Lipfendra as an addition to diet and exercise for adults with high cholesterol.
Lifestyle still matters.
A heart-supportive eating pattern can include:
- Vegetables and fruits
- Beans and lentils
- Whole grains
- Nuts and seeds
- Fish and other lean protein sources
- Unsaturated fats
It is also important to limit excessive saturated and trans fats, remain physically active when medically appropriate, avoid tobacco, and maintain a healthy weight.
What Makes This New Pill Different?
The biggest difference is simple:
It brings a powerful PCSK9-targeting treatment into an oral daily-pill format.
For patients who need substantial LDL reduction and have difficulty with existing treatment options, having another delivery method could make treatment easier to fit into everyday life.
However, the medication is not intended for everyone with mildly elevated cholesterol.
A doctor’s decision will depend on LDL levels, cardiovascular risk, existing treatments, medical history, and individual treatment goals.
One Important Limitation
Lowering LDL is an established way to reduce cardiovascular risk, but the long-term cardiovascular-outcome evidence for enlicitide itself is still being studied. The current approval is based on its demonstrated ability to lower LDL cholesterol.
That distinction is important: a large reduction in a cholesterol measurement is not exactly the same thing as already having completed long-term evidence showing reductions in heart attacks or strokes with this specific drug.
The Bottom Line
The approval of Lipfendra (enlicitide) represents an important development in cholesterol treatment.
It is the first oral PCSK9 inhibitor, is taken once daily, and reduced LDL cholesterol by about 56–59% in the pivotal trials.
For some people with difficult-to-control cholesterol, particularly those who need additional LDL reduction, it could offer a more convenient alternative to injectable PCSK9 treatments.
But it is a prescription medication—not a supplement or a replacement for medical care. Anyone considering it should discuss their cholesterol results and cardiovascular risk with their doctor.